|
|
 Previous Article | Table of Contents | Next Article 
Trisomy 21 in childhood acute lymphoblastic leukemia: a Pediatric Oncology
Group study (8602)
MS Watson, AJ Carroll, JJ Shuster, CP Steuber, MJ Borowitz, FG Behm, DJ Pullen and VJ Land
Department of Pediatrics, Washington University School of Medicine, St
Louis, MO.
Of 1,036 children with newly diagnosed non-T, non-B acute lymphoblastic
leukemia (ALL) and a demonstrated cytogenetic abnormality treated on the
frontline Pediatric Oncology Group (POG) therapeutic trial 8602, there were
33 patients with trisomy 21 as the sole abnormality. Of these 33, 14 had
Down syndrome (DS). Although the non-DS (NDS) trisomy 21 cases tended to be
older than the DS cases, there were no other significant differences in
clinicobiologic features nor in treatment outcomes between the DS and NDS
groups, nor between the entire trisomy 21 group and the other chromosome
abnormality group. Among NDS patients with +21 and one additional
abnormality, +X, +16, -20, and structural abnormalities involving 6q or 12p
were common findings. Kaplan-Meier event-free survival (EFS) curves showed
a 4-year EFS of 80% (SE, 12%) in NDS trisomy 21 cases, 71% (SE, 22%) in DS
cases with trisomy 21 as the sole abnormality, and 69% (SE, 2%) in cases
with other chromosome abnormalities. Trisomy 21 as a sole acquired
abnormality in NDS patients suggests a good prognosis.
Volume 82,
Issue 10,
pp. 3098-3102,
11/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Forestier, S. Izraeli, B. Beverloo, O. Haas, A. Pession, K. Michalova, B. Stark, C. J. Harrison, A. Teigler-Schlegel, and B. Johansson
Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study
Blood,
February 1, 2008;
111(3):
1575 - 1583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Hill, G. Gridley, S. Cnattingius, L. Mellemkjaer, M. Linet, H.-O. Adami, J. H. Olsen, O. Nyren, and J. F. Fraumeni Jr
Mortality and Cancer Incidence Among Individuals With Down Syndrome
Arch Intern Med,
March 24, 2003;
163(6):
705 - 711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Zwaan, G. J. L. Kaspers, R. Pieters, K. Hahlen, G. E. Janka-Schaub, C. H. van Zantwijk, D. R. Huismans, E. de Vries, M. G. Rots, G. J. Peters, et al.
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
Blood,
January 1, 2002;
99(1):
245 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Taub, X. Huang, L. H. Matherly, M. L. Stout, S. A. Buck, G. V. Massey, D. L. Becton, M. N. Chang, H. J. Weinstein, and Y. Ravindranath
Expression of Chromosome 21-Localized Genes in Acute Myeloid Leukemia: Differences Between Down Syndrome and Non-Down Syndrome Blast Cells and Relationship to In Vitro Sensitivity to Cytosine Arabinoside and Daunorubicin
Blood,
August 15, 1999;
94(4):
1393 - 1400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
